Posted by Michael Wonder on 29 Jun 2021
Innovent announces the China NMPA approval of Tyvyt (sintilimab injection) in combination with Byvasda (bevacizumab biosimilar injection) as first-line therapy for people with hepatocellular carcinoma
28 June 2021 - Innovent Biologics today announced that the National Medical Products Administration of China has approved the supplemental new drug application for Tyvyt (sintilimab injection) in combination with Byvasda (bevacizumab biosimilar injection) as a first-line treatment for people with advanced or unresectable hepatocellular carcinoma.
This is the first regulatory approval of a PD-1 inhibitor-based combination therapy for the first-line treatment for hepatocellular carcinoma.
